Research on Gut Health and CBD
Here is a link to the PlusCBDoil.com ‘s National Educator Miles Sarill giving a presentation on CBD and Gut Health…
Regarding Ulcerative Colitis
| 1. | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis.Irving PM, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, Hart A, Murray C, Lindsay JO, Taylor A, Barron R, Wright S.Inflamm Bowel Dis. 2018 Mar 19;24(4):714-724. doi: 10.1093/ibd/izy002.PMID: 29538683 Clinical Trial. |
Regarding Digestive Diseases…
Int J Mol Sci. 2020 May; 21(9): 3067.Published online 2020 Apr 26. doi: 10.3390/ijms21093067PMCID: PMC7246936PMID: 32357565
Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals?
Vicente Martínez,1,2Amaia Iriondo De-Hond,3Francesca Borrelli,4Raffaele Capasso,5,*María Dolores del Castillo,3 and Raquel Abalo6,7
excerpted from the research:
“…Conclusions
Phytocannabinoids exert potent actions throughout the body. Data reported mainly from preclinical research, but also from the available clinical evidence, have demonstrated their high therapeutic potential to treat the diseased GI tract, from functional to organic pathologies. This not only applies to the well-known psychoactive compound, THC, but also to non-psychoactive molecules like CBD and others which have been more scarcely studied so far.
Interestingly, the non-psychoactive phytocannabinoids may be considered as nutraceuticals, and it is envisaged that they will soon find their place, not only in therapy, but in the food industry, leading to new formulations for a healthy life in general, and for a healthy GI tract function, in particular.
The eventual introduction and wide use of hemp-derived non-psychoactive phytocannabinoids as food ingredients will require clearer (and more flexible) regulations, based on clear, evidence-based, scientifically demonstrated, knowledge of their effects and mechanisms of action, which are urgently needed.”
Regarding IBS
| 1. | Long-Term Gastrointestinal Consequences are Frequent Following Sporadic Acute Infectious Diarrhea in a Tropical Country: A Prospective Cohort Study.Rahman MM, Ghoshal UC, Sultana S, Kibria MG, Sultana N, Khan ZA, Ahmed F, Hasan M, Ahmed T, Sarker SA.Am J Gastroenterol. 2018 Sep;113(9):1363-1375. doi: 10.1038/s41395-018-0208-3. Epub 2018 Aug 31.PMID: 30171215 |
| 2. | Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment.Brugnatelli V, Turco F, Freo U, Zanette G.Front Neurosci. 2020 Apr 21;14:371. doi: 10.3389/fnins.2020.00371. eCollection 2020.PMID: 32372912 Free PMC article. No abstract available. |
Regarding Crohn’s and IBD
| 1. | Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial.Naftali T, Mechulam R, Marii A, Gabay G, Stein A, Bronshtain M, Laish I, Benjaminov F, Konikoff FM.Dig Dis Sci. 2017 Jun;62(6):1615-1620. doi: 10.1007/s10620-017-4540-z. Epub 2017 Mar 27.PMID: 28349233 Clinical Trial. |
| 2. | Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study.Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM.Clin Gastroenterol Hepatol. 2013 Oct;11(10):1276-1280.e1. doi: 10.1016/j.cgh.2013.04.034. Epub 2013 May 4.PMID: 23648372 Clinical Trial. |
| 3. | Cannabis Oil Use by Adolescents and Young Adults With Inflammatory Bowel Disease.Hoffenberg EJ, McWilliams S, Mikulich-Gilbertson S, Murphy B, Hoffenberg A, Hopfer CJ.J Pediatr Gastroenterol Nutr. 2019 Mar;68(3):348-352. doi: 10.1097/MPG.0000000000002189.PMID: 30801394 |
| 4. | Anti-Inflammatory Activity in Colon Models Is Derived from Δ9-Tetrahydrocannabinolic Acid That Interacts with Additional Compounds in Cannabis Extracts.Nallathambi R, Mazuz M, Ion A, Selvaraj G, Weininger S, Fridlender M, Nasser A, Sagee O, Kumari P, Nemichenizer D, Mendelovitz M, Firstein N, Hanin O, Konikoff F, Kapulnik Y, Naftali T, Koltai H.Cannabis Cannabinoid Res. 2017 Jul 1;2(1):167-182. doi: 10.1089/can.2017.0027. eCollection 2017.PMID: 29082314 Free PMC article. |
| 5. | An overview of cannabis based treatment in Crohn’s disease.Naftali T.Expert Rev Gastroenterol Hepatol. 2020 Apr;14(4):253-257. doi: 10.1080/17474124.2020.1740590. Epub 2020 Mar 12.PMID: 32149543 |
| 6. | Association between Inflammatory Bowel Disease and Cholelithiasis: A Nationwide Population-Based Cohort Study.Chen CH, Lin CL, Kao CH.Int J Environ Res Public Health. 2018 Mar 14;15(3):513. doi: 10.3390/ijerph15030513.PMID: 29538289 Free PMC article. |
| 7. | Common Digestive and Liver Diseases among 5880 Patients Admitted to Shariati Hospital,Tehran,Iran during 2000-2009.Abedian S, Asl Soleimani H, Saberifiroozi M, Malekzadeh R.Middle East J Dig Dis. 2012 Jan;4(1):28-33.PMID: 24829632 Free PMC article. |
| 8. | Cannabis and Canabidinoids on the Inflammatory Bowel Diseases: Going Beyond Misuse.Carvalho ACA, Souza GA, Marqui SV, Guiguer ÉL, Araújo AC, Rubira CJ, Goulart RA, Flato UAP, Bueno PCDS, Buchaim RL, Barbalho SM.Int J Mol Sci. 2020 Apr 22;21(8):2940. doi: 10.3390/ijms21082940.PMID: 32331305 Free PMC article. Review. |
| 1. | Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis.De Filippis D, Esposito G, Cirillo C, Cipriano M, De Winter BY, Scuderi C, Sarnelli G, Cuomo R, Steardo L, De Man JG, Iuvone T.PLoS One. 2011;6(12):e28159. doi: 10.1371/journal.pone.0028159. Epub 2011 Dec 6.PMID: 22163000 Free PMC article. |
| 2. | Anti-Inflammatory Activity in Colon Models Is Derived from Δ9-Tetrahydrocannabinolic Acid That Interacts with Additional Compounds in Cannabis Extracts.Nallathambi R, Mazuz M, Ion A, Selvaraj G, Weininger S, Fridlender M, Nasser A, Sagee O, Kumari P, Nemichenizer D, Mendelovitz M, Firstein N, Hanin O, Konikoff F, Kapulnik Y, Naftali T, Koltai H.Cannabis Cannabinoid Res. 2017 Jul 1;2(1):167-182. doi: 10.1089/can.2017.0027. eCollection 2017.PMID: 29082314 Free PMC article. |
Regarding Neuropathic Pain and/or Fibromyalgia
| 1. | Cannabis-based medicines for chronic neuropathic pain in adults.Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W.Cochrane Database Syst Rev. 2018 Mar 7;3(3):CD012182. doi: 10.1002/14651858.CD012182.pub2.PMID: 29513392 Free PMC article. Review. |
| 2. | An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia.van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M.Pain. 2019 Apr;160(4):860-869. doi: 10.1097/j.pain.0000000000001464.PMID: 30585986 Free PMC article. Clinical Trial. |
| 3. | [CHARACTERISTICS OF MEDICAL CANNABIS USAGE AMONG PATIENTS WITH FIBROMYALGIA].Habib G, Levinger U.Harefuah. 2020 May;159(5):343-348.PMID: 32431124 Hebrew. |
FDA DISCLAIMER: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
